Oncolys BioPharma, Inc. (4588) Income Statement

Compare

1 Followers

Oncolys BioPharma, Inc. Income Statement

Last quarter (Q2 2025), Oncolys BioPharma, Inc.'s total revenue was ¥28.55M, a decrease of -9.04% from the same quarter last year. In Q2, Oncolys BioPharma, Inc.'s net income was ¥-501.58M. See Oncolys BioPharma, Inc.’s key income statements, including revenue, expenses, profit, and income.

Income Statement	Dec 25	Dec 24	Dec 23	Dec 22	Dec 21
Total Revenue	¥ 28.55M	¥ 31.38M	¥ 63.04M	¥ 976.18M	¥ 642.49M
Gross Profit	¥ 28.30M	¥ 31.38M	¥ 30.61M	¥ 338.49M	¥ 198.80M
Operating Expenses	¥ 2.05B	¥ 1.71B	¥ 1.96B	¥ 1.54B	¥ 1.65B
Depreciation and Amortization	¥ 242.00K	¥ 815.00K	¥ 2.29M	¥ 914.00K	¥ 6.49M
EBITDA	¥ -2.05B	¥ -1.68B	¥ -1.93B	¥ -1.14B	¥ -1.60B
Operating Income	¥ -2.02B	¥ -1.68B	¥ -1.93B	¥ -1.20B	¥ -1.45B
Other Income/Expenses	¥ -29.95M	¥ 388.00K	¥ -5.59M	¥ 58.50M	¥ -157.16M
Pretax Income	¥ -2.05B	¥ -1.68B	¥ -1.94B	¥ -1.15B	¥ -1.61B
Net Income	¥ -2.06B	¥ -1.68B	¥ -1.94B	¥ -1.15B	¥ -1.62B
Per Share Metrics
Basic EPS	¥ -80.00	¥ -77.17	¥ -108.92	¥ -66.31	¥ -95.50
Diluted EPS	¥ -80.00	¥ -77.17	¥ -108.92	¥ -66.31	¥ -95.50
Weighted Average Shares Outstanding	25.73M	21.83M	17.80M	17.33M	16.92M
Weighted Average Shares Outstanding (Diluted)	25.73M	21.83M	17.80M	17.33M	16.92M

Currency in JPY

Oncolys BioPharma, Inc. (4588) Income Statement

Oncolys BioPharma, Inc. Income Statement

Oncolys BioPharma, Inc. Earnings and Revenue History